These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21868415)

  • 1. Paradoxical decrease in serum high-density lipoprotein cholesterol with Tredaptive® (m/r nicotinic acid 1 g and laropiprant 20 mg).
    Sharpe P
    Ann Clin Biochem; 2011 Nov; 48(Pt 6):584-5. PubMed ID: 21868415
    [No Abstract]   [Full Text] [Related]  

  • 2. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
    Masana L; Cabré A; Heras M; Amigó N; Correig X; Martínez-Hervás S; Real JT; Ascaso JF; Quesada H; Julve J; Palomer X; Vázquez-Carrera M; Girona J; Plana N; Blanco-Vaca F
    Atherosclerosis; 2015 Feb; 238(2):213-9. PubMed ID: 25528430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.
    Wi J; Kim JY; Park S; Kang SM; Jang Y; Chung N; Shim WH; Cho SY; Lee SH
    Atherosclerosis; 2010 Nov; 213(1):235-40. PubMed ID: 20855072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
    Parhofer KG
    Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs for hypertriglyceridemia.
    Med Lett Drugs Ther; 2013 Mar; 55(1411):17-9. PubMed ID: 23467119
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
    Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
    J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecule of the Month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides.
    Felts AS
    Curr Top Med Chem; 2008; 8(14):1310. PubMed ID: 18928015
    [No Abstract]   [Full Text] [Related]  

  • 8. Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction.
    Bregar U; Jug B; Keber I; Cevc M; Sebestjen M
    Heart Vessels; 2014 May; 29(3):313-9. PubMed ID: 23712600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Termination of Atherothrombosis Intervention in Metabolic Syndrome with Low High-Density Lipoprotein Cholesterol and High Triglycerides: Impact on Global Health Study and decision to use extended-release niacin in elderly.
    Shil AB
    J Am Geriatr Soc; 2011 Dec; 59(12):2397-8. PubMed ID: 22188098
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination lipid therapy in type 2 diabetes.
    Perkins WJ
    N Engl J Med; 2010 Aug; 363(7):694; author reply 694-5. PubMed ID: 20842773
    [No Abstract]   [Full Text] [Related]  

  • 12. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.
    Bays H; Shah A; Dong Q; McCrary Sisk C; Maccubbin D
    Int J Clin Pract; 2011 Apr; 65(4):436-45. PubMed ID: 21401833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination lipid therapy in type 2 diabetes.
    Saely CH; Rein P; Drexel H
    N Engl J Med; 2010 Aug; 363(7):692; author reply 694-5. PubMed ID: 20701533
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function.
    Ko HS; Kim CJ; Ryu WS
    J Cardiovasc Pharmacol; 2005 Oct; 46(4):405-11. PubMed ID: 16160590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men.
    Johansson JO; Egberg N; Asplund-Carlson A; Carlson LA
    J Cardiovasc Risk; 1997 Jun; 4(3):165-71. PubMed ID: 9475670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
    Scanu AM; Bamba R
    Am J Cardiol; 2008 Apr; 101(8A):44B-47B. PubMed ID: 18375241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.
    Bostom AG; Maclean AA; Maccubbin D; Tipping D; Giezek H; Hanlon WA
    J Clin Lipidol; 2011; 5(4):281-7. PubMed ID: 21784373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: still problematic after the primary publication.
    Brinton EA
    J Clin Lipidol; 2012; 6(4):312-7. PubMed ID: 22836067
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.